CVS Health (CVS): Q1 2026 Earnings Preview and What Investors Should Watch
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $94.98 billion, implying slight growth from $94.6 billion in Q1 2025.
- Consensus adjusted EPS estimate stands at $2.21, a 1.8% decline from $2.25 reported last year.
- CVS Health reaffirmed FY2026 adjusted EPS guidance of $7.00–$7.20, signaling confidence in full-year performance.
- Health Care Benefits segment trends, including Medicare Advantage enrollment and medical costs, are key focuses.
- The company uses a calendar fiscal year, with Q1 covering January–March 2026.
- Stock has risen about 3–5% year-to-date in 2026 amid broader healthcare sector dynamics.
Earnings Context and Why It Matters
As CVS Health's Q1 earnings approach before the market opens on May 6, 2026, I'm paying close attention to how the company is managing its integrated model across retail pharmacy, pharmacy benefits management (PBM), and health insurance through Aetna. With medical costs on the rise and increased regulatory focus on PBM practices and Medicare Advantage (MA) plans, investors like us are looking for evidence of stable margins and membership growth. This report comes after a robust Q4 2025, where full-year revenue reached a record $402.1 billion, even as adjusted EPS came in at $6.75. Shares have climbed modestly year-to-date, and from what I see, the results could shape views on whether CVS can handle ongoing healthcare cost challenges while advancing its turnaround efforts.
Earnings Expectations
Wall Street's consensus points to Q1 revenue of $94.98 billion, according to MarketBeat, marking roughly 0.4% growth from $94.6 billion in the year-ago quarter. This reflects steady pharmacy sales and expansion in Health Services. The adjusted EPS estimate sits at $2.21, a slight dip from $2.25 last year, with Zacks showing a comparable revenue view of $94.37 billion and noting possible pressure from the Health Care Benefits medical loss ratio (MLR, the percentage of premiums spent on care). CVS has surpassed EPS estimates in the past four quarters by an average of 20.6%, frequently helped by favorable prior period development in insurance reserves. One thing that stands out for me is keeping an eye on Pharmacy & Consumer Wellness same-store sales, PBM script trends, and updates on MA membership. The company's FY2026 adjusted EPS guidance of $7.00–$7.20 suggests consistent delivery, backed by at least $9 billion in cash flow from operations.
Market Reaction and Investor Sentiment
Sentiment heading into Q1 feels cautiously optimistic, with CVS shares up about 3.41% year-to-date as of early May 2026, holding up better than some peers thanks to steady guidance. Looking at history, post-earnings reactions have been volatile: across 19 events over five years, positive 1-day returns happened 47% of the time, with median gains of 4.1% on beats and losses of 3.1% on misses. In my view, risks like a higher-than-expected MLR from MA utilization or PBM pricing pressures could weigh on the stock, while beats on guidance might drive gains.
Why I Rely on Tickeron’s AI Screener
In my own research process, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs by filtering on technical patterns, fundamentals, trends, volatility, and AI signals. It lets me scan thousands of stocks and ETFs with customizable criteria like industry, market cap, technical indicators, price patterns, and performance metrics—far more efficiently than manual methods. I've found it particularly useful for spotting trade ideas, trending stocks, breakout candidates, and opportunities in sectors like healthcare. If you're analyzing names like CVS, it's worth checking out to sharpen your edge.
Forward Outlook and Key Factors to Monitor
After Q1, the focus shifts to executing on the reaffirmed FY2026 adjusted EPS guidance of $7.00–$7.20, an increase from 2025's $6.75. This underscores confidence in CVS's vertical integration, though I'm watching Health Care Benefits trends especially closely.
Key areas include Medicare Advantage enrollment, influenced by regulatory changes and star ratings that affect reimbursements. Medical cost trends and MLR remain critical; Q4 2025 highlighted pressures from Inflation Reduction Act changes in Medicare Part D (prescription drug coverage).
In Pharmacy Services, script volume growth and generic dispensing rates will be telling. Retail pharmacy continues to face same-store sales challenges from front-store traffic and drug mix.
Broader elements to track are PBM rebate negotiations, potential M&A activity, and cash flow for dividends or buybacks. Cost controls and digital health initiatives could bolster margins, even as the industry grapples with drug pricing reforms. These dynamics will determine if CVS achieves mid-teens adjusted EPS growth through 2028.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CVS sees MACD Histogram crosses below signal line
CVS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 23, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
CVS moved below its 50-day moving average on August 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CVS crossed bearishly below the 50-day moving average on August 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVS's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in of 342 cases, the price rose further within the following month. The odds of a continued upward trend are .
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 243 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.493) is normal, around the industry mean (3.666). P/E Ratio (24.544) is within average values for comparable stocks, (149.731). CVS's Projected Growth (PEG Ratio) (0.250) is slightly lower than the industry average of (1.216). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.020). P/S Ratio (0.287) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement